Navigation Links
BCM-95 Demonstrates Superior Anti-Inflammatory Effects

GREEN BAY, Wis., Sept. 16 /PRNewswire/ -- Top researchers at the Gastrointestinal Cancer Research Lab at Baylor University Medical Center in Dallas are exploring the clinical applications of BCM-95®, a new patented extract of curcumin with unprecedented potency, and bioavailability.

Previous studies have shown that BCM-95 curcumin was 7-10 times more bioavailable than other forms of curcumin, and had a retention time in the bloodstream between 8 to 12 hours.(1) At all points in the study, BCM-95 curcumin levels were higher than any other form of curcumin tested. This superior absorption and retention is attained by a patented process that involves homogenization and micronization with turmeric essential oil which is then bound to natural plant phospholipids.

"We have the most fascinating and convincing scientific laboratory evidence from thousands of  studies finding that curcumin has potent anti-inflammatory properties," said Ajay Goel, Ph.D., Investigator at the Gastrointestinal Cancer Research Lab at Baylor University. "Abundant data point to the pain-relieving and anti-inflammatory efficacy of curcumin – and these benefits are essentially drawn from its ability to suppress and inhibit the activities of two major pro-inflammatory targets within our cells: NF-kB and COX-2." Dr. Goel's  group was the first to demonstrate that curcumin acts as a specific COX-2 inhibitor, and hence, plays an important role in not only alleviating everyday pain, but has the potential to prevent many chronic diseases that manifest themselves in the background of increased inflammation.

While curcumin holds huge promise as an anti-inflammatory, pain relieving substance, in the human body curcumin is poorly absorbed.  "However, BCM-95 amplifies and potentiates its effectiveness," Dr. Goel explained. "Not only is BCM-95 curcumin absorbed up to 10 times better than conventional curcumin, it also is retained in the body longer. Currently, we have several scientific studies underway in our laboratory on BCM-95, and we are extremely encouraged by the new promising discoveries we are making with this miracle herb."

According to Dr. Goel, inflammation is a factor in 80-90% of all disease. Curcumin demonstrates superior antioxidant and anti-inflammatory effects, and provides liver and heart-protective benefits as well. It is a potent anti-bacterial, anti-fungal, anti-viral, anti-allergenic, and has anti-tumor and anti-cancer properties.

EuroPharma, Inc. is the exclusive distributor of BCM-95® in the U.S. through both the health food store and professional distribution channels. EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. At EuroPharma, Our Passion is Your Health®. For more information on EuroPharma, visit

(1) Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyala S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax) a novel bioenhanced preparation of curcumin. Ind J Pharm Sci. 2008. 2008;70(4):445-450.

SOURCE EuroPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EuroPharma Exclusive Distributor of BCM-95 and BosPure
2. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):